NCT05778591View on ClinicalTrials.gov

Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia

PHASE2RecruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

May 17, 2024

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2026

Conditions

Schizophrenia

Interventions

DRUG

Placebo

Placebo.

DRUG

Buprenorphine 0.15 MG [Belbuca]

Buprenorphine

Trial Locations (1)

90095

RECRUITING

UCLA Semel Institute, Los Angeles

All Listed Sponsors

lead

University of California, Los Angeles

OTHER